| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2026 | Mar, 2026 | Mar, 2026 | Mar, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Orion Corporation Oy (ORINF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Orion Oyj is a producer of pharmaceuticals, pharmaceutical ingredients, and diagnostic tests. The Company is divided into two operating segments: Pharmaceuticals and Diagnostics. The Pharmaceutical segment focuses its products on the nervous system, oncology, respiratory, and critical care. The segment is further divided into four sub-segments: Proprietary Products, Specialty Products, Animal Health, and Fermion. Proprietary Products include drugs that are used in treating Parkinson's, cardiology, and intensive care patients. The Company's Specialty Products include generic drugs, hospital medications, and self-care products. The Animal Health division sells proprietary and generic drugs for domestic pets and livestock. The Fermion sub-segment sells active drug ingredients to other companies. The Diagnostics segment produces in vitro tests and systems for patients. This segment focuses on facilitating diagnosis and treatment of patients. The Diagnostic products are entered on point-of-care tests, which are meant to be usable without laboratory work. The Company sells its products to doctors, veterinarians, pharmacies, hospitals, clinics, and medical laboratories.